Aciclovir Market 2020: Latest Report with Emerging Trends, Share and Leading Players (Sanofi, Mylan, Orion Pharma, Pfizer, Teva, Arrow) | Foreseen Till 2024

Aciclovir Market 2020 Global Industry research report studies latest Aciclovir industry aspects market size, share, trends, growth, business overview and Aciclovir industry scenario during the forecast period (2020-2024).

Global Aciclovir Market overview:

BIR Analyst covers the Major Players data, including: shipment, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including market size.

Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/258564 .

Aciclovir, also known as acyclovir, is an antiviral medication. It is primarily used for the treatment of herpes simplex virus infections, chickenpox, and shingles. Other uses include prevention of cytomegalovirus infections following transplant and severe complications of Epstein-Barr virus infection. The Global Aciclovir Market is segmented on the basis of Product Type, Application, End Use Industry and Region.

On the Basis of Product Type segment, the Aciclovir Market is sub segmented into Generic and Patent. Based on End Use Industry segment, the Aciclovir Market is sub segmented into Hospitaland Drug Store.

Some of the Aciclovir Market manufacturers involved in the market are Greater Pharma, LBS Labs, GlaxoSmithKline, Lex Ano, Salutas, Novartis, Teva, Stada Nordic, Cimed Industria de Medicamentos, Reman Drug, L.E.T.I., Nichi-Iko Pharmaceutical, Choseido Pharmaceutical, Shiono Kemikaru, Towa Yakuhin, Wockhardt, Takata Pharmaceutical, Aliud, Amneal Pharma, Apotex, Arrow, Laboratoires Servier, Sanofi, Mylan, Orion Pharma, Pfizer in World, effective mergers are some of the strategies adopted by the Aciclovir Market manufacturers. New product launches and continuous technological innovations are the Aciclovir Market strategies adopted by the major players.

Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on "Aciclovir Market Report 2020" @ https://www.businessindustryreports.com/buy-now/258564/single .

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study.

There are several manufacturers of Aciclovir in Europe and North America. In North America, the demand for Aciclovir is primarily driven by the healthcare sector. Among the countries in Asia Pacific, the demand was substantially high in developing countries such as China and India. These countries have been witnessing rapid increase in its population along with expansion of their overall economies, which has led to increase in disposable income.

Grab Your Report at an Impressive Discount @ https://www.businessindustryreports.com/check-discount/258564 .

Top Industry News:

Mylan and Lupin Announce Positive CHMP Opinion for Nepexto, Biosimilar Etanercept on March 27, 2020 -- Mylan N.V. and Lupin Limited today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Nepexto, a biosimilar to Enbrel (etanercept), for all indications of the reference product including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis (including ankylosing spondylitis and non-radiographic axial spondyloarthritis), plaque psoriasis and paediatric plaque psoriasis.

The positive CHMP opinion is based on a biosimilarity assessment which included preclinical and clinical studies demonstrating bioequivalence to the reference product. In addition, a phase 3 clinical studyi in patients with moderate-to-severe active rheumatoid arthritis confirmed equivalence of Nepexto to the reference product in terms of efficacy, safety and immunogenicity.

The CHMP positive opinion will now be considered by the European Commission (EC). Once approved the EC will grant a centralized marketing authorization for member countries of the EU. The decision on the EC's approval is expected in May 2020.

Mylan President Rajiv Malik commented, "We are pleased with the positive CHMP opinion for Nepexto, biosimilar etanercept. This recommendation validates the strong scientific program supporting this important treatment, which is one of 20 products in our broad and diverse biosimilars portfolio, and our shared commitment with Lupin to help increase access to more affordable biologic treatments, such as etanercept, in Europe and many other regions around the world."

Table of Contents:

1 Aciclovir Product Definition
2 Global Aciclovir Market Manufacturer Share and Market Overview
2.1 Global Manufacturer Aciclovir Shipments
2.2 Global Manufacturer Aciclovir Business Revenue
2.3 Global Aciclovir Market Overview
3 Manufacturer Aciclovir Business Introduction
3.1 Greater Pharma Aciclovir Business Introduction
3.1.1 Greater Pharma Aciclovir Shipments, Price, Revenue and Gross profit 2020-2024
3.1.2 Greater Pharma Aciclovir Business Distribution by Region
3.1.3 Greater Pharma Interview Record
3.1.4 Greater Pharma Aciclovir Business Profile
3.1.5 Greater Pharma Aciclovir Product Specification
3.2 LBS Labs Aciclovir Business Introduction
3.2.1 LBS Labs Aciclovir Shipments, Price, Revenue and Gross profit 2020-2024
3.2.2 LBS Labs Aciclovir Business Distribution by Region
3.2.3 Interview Record
3.2.4 LBS Labs Aciclovir Business Overview
3.2.5 LBS Labs Aciclovir Product Specification
3.3 GlaxoSmithKline Aciclovir Business Introduction
3.3.1 GlaxoSmithKline Aciclovir Shipments, Price, Revenue and Gross profit 2020-2024
3.3.2 GlaxoSmithKline Aciclovir Business Distribution by Region
3.3.3 Interview Record
3.3.4 GlaxoSmithKline Aciclovir Business Overview
3.3.5 GlaxoSmithKline Aciclovir Product Specification
3.4 Lex Ano Aciclovir Business Introduction
3.5 Salutas Aciclovir Business Introduction
3.6 Novartis Aciclovir Business Introduction
................... Request free sample to get a complete Table of Content

About us

BusinessindustryReports.com is digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined - we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune - India

sales@businessindustryreports.com

+19376349940

This release was published on openPR.